Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31
Phase 41

Trial Status

Other2

Role Distribution

Principal Investigator1
Other Roles1
PI Rate50%

Activity Timeline

Clinical Trials (2)

NCT05311943Phase 3Unknown
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
Chronic Myeloid Leukemia, Chronic PhaseOlverembatinibTyrosine Kinase Inhibitors
StudychairStart date: 2022-07-01
NCT04677439Phase 4Unknown
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Chronic Myeloid Leukemia, Chronic PhaseFlumatinibImatinib
PrincipalinvestigatorStart date: 2021-01-01

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT05311943Phase 3StudyChair

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Chronic Myeloid Leukemia, Chronic PhaseOlverembatinibTyrosine Kinase Inhibitors
Unknown
NCT04677439Phase 4PrincipalInvestigator

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Chronic Myeloid Leukemia, Chronic PhaseFlumatinibImatinib
Unknown

All 2 trials loaded